A development stage precision gene therapy company dedicated to pioneering the development of targeted therapies based on our next-generation AAV vectors. Our proprietary Therapeutic Vector Evolution platform enables our“disease first” approach to product discovery and development, thereby allowing us to customize our AAV vectors to target specific tissue types associated with the underlying disease.
Lead Underwriter
Evercore Group L.L.C ,Goldman Sachs & Co. LLC ,William Blair and Co., L.L.C.
